Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07017023

Combined Blood Pressure Medication and Activity Scheduling for Low Mood

This study explores the effects of 7-day losartan (50mg) versus placebo with brief behavioural activation on emotional processing in young volunteers low in positive mood

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Warneford Hospital, University of Oxford

Oxford, Oxfordshire, OX37JX, United Kingdom

Location status: Recruiting

Location contact

Andrea Reinecke, PhD

CONTACT

[email protected]

01865 618320

Andrea Reinecke, PhD

PRINCIPAL_INVESTIGATOR

Rowan Haslam, MSc

CONTACT

[email protected]

About this study

Behavioural Activation (BA) is a first-line treatment for depression that aims to re-engage patients with rewarding activities, to improve mood. However, patients with low levels of positive mood respond less well to BA than others. Neuroscience has identified deficits in the processing of positive stimuli in this group of people, using cognitive-psychological computer tasks and brain imaging. Losartan, a licensed medication targeting the renin-angiotensin system, has recently been found to improve the processing of positive stimuli in healthy volunteers. Combining losartan with BA may improve treatment response in people with low positive mood, by improving positive information processing. This study will test this hypothesis.

In a double-blind randomised trial, 76 participants with low positive mood will receive 7-day behavioural activation (BA) with daily losartan (50mg) or placebo. Before and after the intervention, they will complete computer tasks measuring processing of positive and negative information.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to provide informed consent
  • Aged 18-65 years
  • Self-reported low levels of positive mood
  • Sufficient written and spoken English skills to understand study procedures
  • Normal or corrected to normal vision and hearing
  • Access to a computer and reliable internet connection

Exclusion criteria

  • Antidepressant treatment or medication in last three months
  • Currently receiving cognitive-behavioural therapy with behavioural activation
  • History of psychosis or bipolar disorder
  • History of substance dependence
  • Use of illegal drugs in last 3 months
  • First-degree relative with history of psychosis or bipolar disorder
  • Current or past hospitalisation for mental health reasons
  • BDI-II score >30
  • Judged to be currently at clinical risk of suicide
  • Past suicide attempt
  • CNS-medication last 6 weeks (including in another study)
  • Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medic
  • Current blood pressure or other heart medication
  • Diagnosis of intravascular fluid depletion or dehydration
  • History of angioedema
  • Impaired kidney function (based on self-report)
  • Very low blood pressure following established definitions (at least three consecutive measurements of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90/60 mmHg (in accordance with established standard definitions: https://www.nhs.uk/cond...-pressure-hypotension/)
  • Current diagnosis of a developmental disorder (e.g. ADHD, Tourette's syndrome, severe learning disability) according to self-report, where in the opinion of the study team such difficulties would likely interfere with compliance or task performance
  • Current diagnosis of a neurological disorder (e.g. epilepsy, MS) according to self-report
  • Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may put the participant at risk when participating, or may influence compliance or task performance
  • Pregnancy (urine pregnancy test during Baseline Visit), breast feeding or plans to become pregnant during study participation
  • Heavy use of cigarettes (smoke > 20 cigarettes per day)
  • Severe lactose intolerance (due to losartan containing some lactose monohydrate)

Treatment and study plan

Losartan with BA

Drug

7-day losartan (Cozaar, 50mg; oral tablet) with 7-day BA

Placebo with BA

Other

7-day placebo (oral; microcellulose in identical capsules) with 7-day BA

Primary outcomes

  1. Change in reinforcement learning

    Time frame: from baseline to post 7-day intervention

    reinforcement learning, calculated as the learning rate from negative and positive decision outcomes. Larger scores indicate better learning from an outcome.

Secondary outcomes

  1. Change in approach-avoidance-task (AAT) effect score

    Time frame: from baseline to post 7-day intervention

    mean reaction time of the pull trials of a valence category subtracted from the push trials of the same category, yielding a single indicator of approach/avoidance, with positive scores indicating relatively stronger approach and negative scores indicating relatively stronger avoidance

  2. Change in social approach decisions

    Time frame: from baseline to post 7-day intervention

    % approach vs avoid decisions

  3. Change in motivational effort in the Apples Task

    Time frame: from baseline to post 7-day intervention

    The task weighs effort costs against reward value. It involves a hand dynamometer to record effort. On each trial, participants receive an offer showing a reward (number of apples shown on a tree) and an effort level (height of marking on the tree trunk), which they can accept or reject (Yes/No response). On a subset of accepted trials, participants have to exert physical effort on the hand dynamometer to earn the reward (number of apples in the respective trial). Participants receive monetary reward for the number of apples collected. Key outcome marker is effort-reward valuation, i.e. % accepted trials based on combinations of effort and reward levels. Other outcomes: Force exerted relative to Maximum Voluntary Contraction (MVC), Reaction times of Yes/No.

Study contacts

Contact information is provided by the study sponsor or research team.

Andrea Reinecke, PhD

CONTACT

[email protected]

01865 618320

Rowan Haslam, MSc

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University of Oxford

Other

Registry information

Official study title

Cognitive Effects of Losartan-augmented Behavioural Activation in Anhedonia

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 12, 2025
Registry last updated
Jul 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.